Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05026749 · ClinicalTrials.gov registry record · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
A Phase 3 study of Respiratory Syncytial Virus Infections, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
- 15
- Study locations
NCT05026749 is a Phase 3 study of Respiratory Syncytial Virus Infections that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 370 participants, below the 1,074-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (66% lower). The trial reports 15 study locations across 14 states.
The verdict
NCT05026749, a Phase 3 study of Respiratory Syncytial Virus Infections, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
- 15
- Study locations
Study Summary
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Conditions Studied
Interventions
- OTHER Control Group
- DRUG AZM Group
Study Locations (15)
Ohio
- Rainbow Babies and Children's Hospital - Cleveland
- Nationwide Children's Hospital - Columbus
Alabama
- The University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Children's National Hospital - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Riley Children's Health - Indianapolis
Missouri
- St. Louis Children's Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2022-02-27 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05026749
The ClinicalTrials.gov registry entry for NCT05026749 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,074-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (66% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT05026749 reports 15 study locations spanning 14 distinct geographic areas - top geographies include Ohio, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05026749 about?
NCT05026749 is a clinical study titled "Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children". The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
What is the current status of trial NCT05026749?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2022-02-27. Estimated completion is 2028-07-31.
What conditions does trial NCT05026749 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT05026749?
The interventions under investigation include: Control Group (OTHER), AZM Group (DRUG).
Who is sponsoring clinical trial NCT05026749?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05026749 being conducted?
This trial has 15 study locations across Alabama, California, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
ACTIVE NOT RECRUITING · Phase 3
-
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
COMPLETED · Phase 3
-
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
COMPLETED · Phase 3
-
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
COMPLETED · Phase 3
-
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.